FindTrial
Sign In

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS: A Preliminary Randomized Controlled Clinical Trial

"ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS: A Preliminary Randomized Controlled Clinical Trial - "ADDITIONAL VALUE" OF NASAL THERAPY IN STANDARD THERAPY FOR COVID-19 PATIENTS WITH OLFACTORY DISORDERS: A Preliminary Randomized Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000045185
Enrollment
24
Registered
2021-08-18
Start date
2020-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

olfactory disorder in COVID-19

Interventions

COVID standar Therapy for 2 weeks COVID standar Therapy and nasal treatment (mometasone nasal spray 2dd2 spray, normosaline nasal irrigation 2dd30 cc both nostrils, oxymethazolin 0,5% nasa spray 1dd2

Sponsors

there were no sponsors available
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Confirmed Sars-COV2 PCR positive with mild or moderate symptomps 2. Impaired Alcohol Swab test result 3. Cooperative

Exclusion criteria

Exclusion criteria: 1. Cognitive and conciousness impairment 2. Severe dyspnea and unstable vital sign 3. History of olfactory and taste disturbance before COVID 4. History of chronic rhinosinusitis and severe head trauma 5. History of routine use of steroid intranasal, decongestan before COVID-19 6. History of skin and vascular problem

Design outcomes

Primary

MeasureTime frame
improvement of olfactory disorders both subjective (visual analog score) and objective by Alcohol sniff test and Intravenous olfaction test results after treatment—

Countries

Asia(except Japan)

Contacts

Public Contactindra pamungkas

ORL-HNS Departement CIpto Mangunkusumo General Hospital Oncology-Rhinology

indraparmaditya@gmail.com6281314319179

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026